Circio Holding ASA (OSL:CRNA)
Norway · Delayed Price · Currency is NOK 0.6000
-0.0290 (-4.61%)
At close: Aug 15, 2025
Circio Holding ASA Company Description
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines.
The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells.
It has a collaboration with Certest Biotec, S.L. for formulation of circVec.
The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023.
The company was incorporated in 2010 and is based in Oslo, Norway.
Circio Holding ASA
| Country | Norway |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Erik Wiklund |
Contact Details
Address: Universitetsgata 2 Oslo, 0164 Norway | |
| Phone | 47 929 51 788 |
| Website | circio.com |
Stock Details
| Ticker Symbol | CRNA |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0013033795 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Erik Digman Wiklund | Chief Executive Officer |
| Dr. Lubor Gaal Ph.D. | Chief Financial Officer and Head of BD |
| Ola Melin | Chief Operating Officer |
| Dr. Thomas Birkballe Hansen | Chief Technology Officer |
| Dr. Victor Levitsky M.D., Ph.D. | Chief Scientific Officer |
| Jon Amund Eriksen M.Sc., MSc | Special Advisor |
| Prof. Gustav Gaudernack Ph.D. | Chief Scientific Adviser |
| Dr. Peter Skorpil Ph.D. | Vice President of Business Development |